MTOR and breast cancer: As noted above, mutations in PI3K-AKT-mTOR pathway genes are frequently observed in ERα+ breast cancers and at least 50% of breast cancers with ESR1 mutation/amplifications displayed genomic aberrations of this pathway (Figure 2).